NCT07465835 A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
| NCT ID | NCT07465835 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Electra Therapeutics Inc. |
| Condition | T Cell Malignancies |
| Study Type | INTERVENTIONAL |
| Enrollment | 84 participants |
| Start Date | 2026-02-17 |
| Primary Completion | 2028-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 84 participants in total. It began in 2026-02-17 with a primary completion date of 2028-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a Phase 1, two-part, multicenter study to evaluate ELA026 in participants ≥18 years old with relapsed/refractory TCM following any line of prior therapy who are eligible for investigational treatments.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years Participants with a confirmed histologic diagnosis of a TCM who are R/R following any line of prior therapy (participants with CTCLs should have received at least 2 prior lines of systemic therapy for R/R CTCL) and eligible for investigational therapies * Presence of measurable disease by clinical examination, radiologic imaging (computed tomography, magnetic resonance imaging, or whole body FDG-PET scans), and/or in bone marrow aspirate/biopsy * Eastern Cooperative Oncology Group performance score of ≤2 * Anticipated life expectancy \>6 months per investigator judgment Exclusion Criteria: * Participants who are eligible for standard of care or approved therapeutic options for R/R TCMs with established clinical benefit * Organ dysfunction as defined in the protocol * Participants with hemophagocytic lymphohistiocytosis (HLH) based on HLH2004 diagnostic criteria * Participants receiving or planning to start immunotherapy or immune effector cell therapy (such as chimeric antigen receptor \[CAR\] T-cell therapy, T-cell engagers, or programmed cell death protein 1 \[PD1\]/programmed cell death ligand 1 \[PD-L1\] inhibitors) * Allogeneic hemopoietic stem cell transplant within 100 days prior to the first dose of ELA026 and currently receiving systemic immunosuppressive therapy * Women of childbearing potential who are planning to become pregnant or are breastfeeding during the conduct of the study, including 60 days after last dose of study drug * Male participants whose partners are women of childbearing potential and who are planning to become pregnant during the conduct of this trial by the male partner, including within 60 days after the last dose of study drug
Contact & Investigator
Clinical Trials Electra Clinical Trials Information
✉ clinicaltrials@electra-therapeutics.com📞 Please email
Frequently Asked Questions
Who can join the NCT07465835 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying T Cell Malignancies. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07465835 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07465835 currently recruiting?
Yes, NCT07465835 is actively recruiting participants. Contact the research team at clinicaltrials@electra-therapeutics.com for enrollment information.
Where is the NCT07465835 trial being conducted?
This trial is being conducted at New Haven, United States, Atlanta, United States, Grand Rapids, United States, New York, United States and 2 additional locations.
Who is sponsoring the NCT07465835 clinical trial?
NCT07465835 is sponsored by Electra Therapeutics Inc.. The trial plans to enroll 84 participants.